米诺膦酸或地舒单抗预防亚洲前列腺癌患者雄激素剥夺治疗相关骨丢失的随机对照试验
PROMADE研究为多中心开放标签随机对照试验,纳入147例接受雄激素剥夺治疗(ADT)的激素敏感性前列腺癌无骨转移亚洲男性,随机分为米诺膦酸组、地舒单抗组和对照组。结果显示,两种药物均显著改善腰椎和全髋骨密度(BMD),且显著降低骨转换标志物,提示可用于预防ADT相关骨丢失。
要点
- 米诺膦酸和地舒单抗均显著提高ADT患者腰椎BMD(分别2.5%和4.0%),对照组为-0.1%。
- 地舒单抗增加股骨颈和全髋BMD,米诺膦酸仅增加全髋BMD。
- 两种药物均显著降低12个月骨转换标志物,可用于预防ADT相关骨丢失。
核心结论
- 米诺膦酸或地舒单抗可用于预防亚洲前列腺癌患者ADT相关骨丢失。
研究设计与样本
- 多中心、开放标签、随机对照研究,纳入147例接受ADT的激素敏感性前列腺癌无骨转移患者,随机(1:1:1)分为米诺膦酸组、地舒单抗组和对照组。
主要发现
- 腰椎BMD平均百分比变化:米诺膦酸组2.5%(p<0.05)、地舒单抗组4.0%(p<0.01),对照组-0.1%。
- 地舒单抗增加股骨颈和全髋BMD,米诺膦酸仅增加全髋BMD(与对照组比均p<0.05)。
- 12个月骨转换标志物百分比变化在米诺膦酸组和地舒单抗组均显著低于对照组(均p<0.01)。
关键数值与推荐
- 主要终点为12个月腰椎BMD平均百分比变化;次要终点包括股骨颈和全髋BMD平均百分比变化及骨转换标志物变化。
临床怎么用
- 对于接受ADT的亚洲前列腺癌患者,可考虑使用米诺膦酸或地舒单抗预防骨丢失。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: There is still a lack of evidence that minodronate or denosumab prevents bone loss due to androgen deprivation therapy (ADT) in non-Western patients. This study showed that both drugs significantly improved lumbar spine and total hip bone mineral density in Asian men with prostate cancer who received ADT. INTRODUCTION: To evaluate whether monthly oral minodronate or semiannual subcutaneous injection of denosumab improves bone mineral density (BMD) in Asian men with prostate cancer (PCa) receiving ADT. METHODS: A multicenter, open-label, randomized, controlled study including patients with hormone-sensitive PCa without bone metastasis receiving ADT was performed. Patients were randomized (1:1:1) to minodronate, denosumab, or no agent control groups. The primary end point was the mean percentage change in BMD at the lumbar spine at 12 months. Secondary end points were the mean percentage change in BMD at the femoral neck and total hip and changes in bone turnover markers. Statistical comparison was performed using analysis of covariance. RESULTS: Of the 147 subjects enrolled in this study, 102 were randomly assigned into the minodronate (n = 36), denosumab (n = 36), and control (n = 30) groups. The percentage change in BMD at the lumbar spine was significantly improved in the minodronate (2.5%, p < 0.05) and denosumab groups (4.0%, p < 0.01) compared with that in the control group (- 0.1%). Denosumab increased BMD at the femoral neck and total hip at 12 months, whereas minodronate only increased BMD at the total hip compared with controls (all p < 0.05). The percentage change in bone turnover markers at 12 months was significantly lower in the minodronate and denosumab groups compared with that in the control group (both p < 0.01). CONCLUSION: Minodronate or denosumab can be used for preventing bone loss related to ADT in Asian patients with PCa.
引用
- Yoshida T, Kinoshita H, Taniguchi H, et al. A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study. Osteoporos Int. 2020. PMID: 31993719. doi:10.1007/s00198-019-05271-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。